MedTrace Logo

Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy

NCT01082224 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 440

Last updated 2023-07-07

No results posted yet for this study

Summary

RATIONALE: Diagnostic procedures, such as contrast-enhanced CT scan and contrast-enhanced MRI, may help find liver cancer and find out how far the disease has spread.

PURPOSE: This clinical trial is studying contrast-enhanced CT scan and contrast-enhanced MRI in diagnosing and staging liver cancer in patients with chronic liver disease.

Conditions

Interventions

DRUG

iodinated contrast dye

iodinated Radiocontrast dye for imaging enhancement

DRUG

motexafin gadolinium

motexafin gadolinium

OTHER

Eovist-enhanced MRI

A sub-study introduces the Eovist contrast agent for MRI scans at the same time points as the parent policy-assessment trial.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • American College of Radiology Imaging Network

    lead NETWORK

Principal Investigators

  • Christoph Wald, MD, PhD · Lahey Clinic Medical Center - Burlington

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01082224 on ClinicalTrials.gov